• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Egetis Therapeutics

5.63 SEK

-8.46 %

Less than 1K followers

EGTX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-8.46 %
-11.06 %
+5.83 %
+5.43 %
+6.23 %
+30.32 %
+13.74 %
+8.99 %
-59.31 %

Egetis Therapeutics is a pharmaceutical company focused on developing innovative treatments for rare diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business has a global presence and serves customers worldwide. Egetis Therapeutics was founded in 2006 and is headquartered in Stockholm, Sweden.

Read more
Market cap
2.76B SEK
Turnover
6.22M SEK
Revenue
62.4M
EBIT %
-544.71 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
21/8
2026

Interim report Q2'26

6/11
2026

Interim report Q3'26

Press release2026-06-10 15:00

Egetis meddelar att Behind the Mystery-avsnittet om MCT8-brist sänds i repris på Lifetime-kanalen i USA

Egetis Therapeutics
Press release2026-06-10 15:00

Egetis Therapeutics Announces National Re-Airing of Behind the Mystery Episode on Lifetime Spotlighting MCT8 Deficiency

Egetis Therapeutics
Regulatory press release2026-05-29 10:00

Change in the number of shares and votes in Egetis Therapeutics

Egetis Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-05-29 10:00

Ändring av antalet aktier och röster i Egetis Therapeutics

Egetis Therapeutics
Press release2026-05-19 14:00

Egetis presenterar drivkrafter för vårdresursanvändning och kostnader vid MCT8‑brist på ISPOR 2026

Egetis Therapeutics
Press release2026-05-19 14:00

Egetis to present healthcare resource drivers and cost in MCT8 deficiency at ISPOR 2026

Egetis Therapeutics
Press release2026-05-13 16:45

Utnyttjande av optioner i personaloptionsprogram och meddelande om insynshandel

Egetis Therapeutics
Press release2026-05-13 16:45

Exercise of options under employee stock option program and notification of insider trading

Egetis Therapeutics
Press release2026-05-07 10:00

Egetis Therapeutics deltar vid ledande medicinska konferenser under 2026

Egetis Therapeutics
Press release2026-05-07 10:00

Egetis Therapeutics to Participate in Leading International Medical Conferences in 2026

Egetis Therapeutics
Press release2026-05-05 08:00

Egetis meddelar att patent för sammansättning för MCT8‑brist har beviljats i USA

Egetis Therapeutics
Press release2026-05-05 08:00

Egetis Announces Grant of Patent for MCT8 Deficiency Composition in the U.S.

Egetis Therapeutics
Press release2026-04-30 12:30

Egetis Therapeutics deltar vid Pediatric Endocrine Society Annual Meeting 2026

Egetis Therapeutics
Press release2026-04-30 12:30

Egetis Therapeutics to Participate in Pediatric Endocrine Society Annual Meeting 2026

Egetis Therapeutics
Regulatory press release2026-04-30 09:05

Ändring av antalet aktier och röster i Egetis Therapeutics

Egetis Therapeutics
Regulatory press release2026-04-30 09:05

Change in the number of shares and votes in Egetis Therapeutics

Egetis Therapeutics
Egetis Therapeutics, Audiocast, Q1'26
Webcast2026-04-29 10:00

Egetis Therapeutics, Audiocast, Q1'26

Egetis Therapeutics
Regulatory press release2026-04-29 07:00

Kvartalsrapport Q1 2026

Egetis Therapeutics
Regulatory press release2026-04-29 07:00

Interim report Q1 2026

Egetis Therapeutics
Press release2026-04-24 11:00

Inbjudan till presentation av Egetis kvartalsrapport Q1 2026 den 29 april 2026

Egetis Therapeutics